Search clinical trials for: dornase alfa [Pulmozyme®]

Total 319 results

University of Colorado, Denver
Genentech, Inc.

Completed

Treatment of Clogged Tympanostomy Tubes: An Off-Label Use of Dornase Alfa (Pulmozyme®)

Otitis Media

United States
Genentech, Inc.

Completed

A Study of the Comparable Efficacy and Safety of Pulmozyme (Dornase Alfa) Delivered by the eRapid Nebulizer System in Patients With Cystic Fibrosis

Cystic Fibrosis

United States
AO GENERIUM

Completed

Efficacy and Safety of Tigerase® vs. Pulmozyme® in Patients With Cystic Fibrosis

Fibrosis | Cystic Fibrosis

Russian Federation
University of Vermont
Genentech, Inc.

Completed

Nasally Delivered Pulmozyme for Sinusitis in Cystic Fibrosis

Sinusitis | Cystic Fibrosis

United States
University of Melbourne

Recruiting

Improving Early Reperfusion With Adjuvant Dornase Alfa in Large Vessel Ischemic Stroke (EXTEND-IA DNase)

Ischemic Stroke

Australia
Nicole Hamblett
University of Washington; Dartmouth-Hitchcock Medical Center; Cystic Fibrosis...

Completed

Impact of Discontinuing Chronic Therapies in People With Cystic Fibrosis on Highly Effective CFTR Modulator Therapy (SIMPLIFY)

Cystic Fibrosis

United States
Boston Children's Hospital
Brigham and Women's Hospital; South Shore Hospital

Recruiting

Pulmozyme to Improve COVID-19 ARDS Outcomes

COVID

United States
Genentech, Inc.

Terminated

A Study of Pulmozyme® (Dornase Alpha) in 3- to 5-Year-Old Patients With Cystic Fibrosis

Cystic Fibrosis
Genentech, Inc.

Terminated

A Trial of Pulmozyme Withdrawal on Exercise Tolerance in Cystic Fibrosis Subjects With Severe Lung Disease (TOPIC)

Cystic Fibrosis

United States
University of Jena

Completed

Nasal Inhalation of Pulmozyme in Patients With Cystic Fibrosis and Chronic Rhinosinusitis

Cystic Fibrosis | Rhinosinusitis

Germany
University of Medicine and Dentistry of New Jersey

Completed

Impact of Nebulized Dornase Alpha on Mechanically Ventilated Patients

Atelectasis | Ventilation, Mechanical

United States
Nicole Hamblett
University of Washington; Dartmouth-Hitchcock Medical Center; Cystic Fibrosis...

Completed

Impact of Discontinuing Dornase Alfa in People With CF on Highly Effective CFTR Modulator Therapy-A SIMPLIFY Sub-Study (SIMPLIFY-DN)

Cystic Fibrosis

United States
UConn Health

Withdrawn

Pulmozyme for Sjogren's Associated Cough

Cough | Sjogren's Syndrome

United States
University College, London

Completed

Nebulised Dornase Alfa for Treatment of COVID-19 (COVASE)

Hypoxia | COVID19

United Kingdom
University of Missouri-Columbia

Completed

Dornase Alfa for ARDS in Patients With Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) (DORNASESARS2)

SARS-CoV 2 | ARDS

United States
Georgetown University
Genentech, Inc.

Completed

Dornase Alfa Therapy for Ventilator Associated Lung Infections in the Neonatal Intensive Care Unit (NICU) (PVAIN)

Pulmonary Infections

United States
Fondation Ophtalmologique Adolphe de Rothschild
University Hospital, Strasbourg, France; Centre Hospitalier Régional Metz-Thionville

Terminated

Efficacy and Safety of aerosolizedDornase Alfa Administration in Patients With COVID19 Induced ARDS (COVIDORNASE) (COVIDORNASE)

COVID-19 | Acute Respiratory Distress Syndrome

France
Ludwig-Maximilians - University of Munich
University Hospital Erlangen; University Hospital Regensburg

Not yet recruiting

Reduction of SystemiC Inflammation After Ischemic Stroke by Intravenous DNase Administration (ReSCInD) (ReSCInD)

Ischemic Stroke | Inflammatory Response

Germany
Northwestern University
Genentech, Inc.

Unknown

Pilot Study of Pulmozyme (rhDNase) in Patients With Head and Neck Cancers Treated With Radiation Therapy + Chemotherapy

Head and Neck Cancer

United States
The Alfred
The Alfred Research Trusts Small Project Grant.; Dr Carey Denholm and Laura...

Completed

Preliminary Study of Dornase Alfa to Treat Chest Infections Post Lung Transplant.

Lower Respiratory Tract Infection | Lung Transplant Infection

Australia
University Hospital Tuebingen
Joachim Riethmueller, Dr. med.

Unknown

Time of Ventilation and Lung Function of Ventilated Patients Under Therapy With Dornase Alfa

Long Term Ventilation

Germany
Milton S. Hershey Medical Center
Genentech, Inc.

Withdrawn

Pulmozyme in Cystic Fibrosis With Sinusitis

Sinusitis | Cystic Fibrosis

United States
The Hospital for Sick Children
Canadian Institutes of Health Research (CIHR); Unity Health Toronto; Children... and other collaborators

Completed

Intrapleural DNase and Tissue Plasminogen Activator in Pediatric Empyema (DTPA Trial)

Pleural Empyema

Canada
JHL Biotech, Inc.

Completed

A Comparative Safety and Pharmacokinetic Study of JHL1922 and Pulmozyme® in Healthy Subjects

Healthy Subjects

Netherlands
Pharmaxis

Completed

Comparison of Inhaled Mannitol and rhDNase in Children With Cystic Fibrosis

Cystic Fibrosis

United Kingdom
Azienda Ospedaliera di Padova
Hoffmann-La Roche

Unknown

Dornase Alfa and Urokinase for Kids With Pleural Empyema (DUKE)

Pleural Empyema

Italy
Fondation Ophtalmologique Adolphe de Rothschild

Recruiting

Efficacy of Pulmozyme® on Arterial Recanalization in Post-thrombectomy Patients Managed for Ischemic Stroke (NETs-target) (NETs-target)

Ischemic Stroke

France
University Hospital, Strasbourg, France

Recruiting

Inhaled Dornase Alpha to Reduce Respiratory Failure After Severe Trauma (TRAUMADORNASE)

Multiple Trauma | Respiratory Distress Syndrome, Adult

France
University Medical Centre Ljubljana

Terminated

Usefulness of DORNASE in COVID-19 on HFNO

COVID-19 Pneumonia

Slovenia
Nationwide Children's Hospital
Genentech, Inc.

Completed

Effectiveness of Pulmozyme in Infants With Cystic Fibrosis

Cystic Fibrosis

United States
Jon Simmons
University of South Alabama

Recruiting

Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure (DAMPENCOVID)

Covid19

United States
University of Illinois at Chicago
Genentech, Inc.; Research to Prevent Blindness

Terminated

DNase Treatment for Dry Eyes

Dry Eye

United States
Eastern Regional Medical Center

Recruiting

Combination Tissue Plasminogen Activator (Tpa) and Dornase Alfa (Dnase) Administration Through Intrapleural Catheters for the Treatment of Loculated or Non-Draining Malignant Pleural Effusions

Loculated or Non-draining Malignant Pleural Effusions

United States
National University of Malaysia

Completed

Short Duration High Intensity Intrapleural Alteplase With Pulmozyme in Pleural Infection Management

Loculated Empyema

Malaysia
AO GENERIUM

Completed

Tigerase® Efficacy and Safety as Part of Complex Therapy in Patients With COVID-19

COVID-19 | Coronavirus Disease 2019

Russian Federation
University of Leipzig

Recruiting

The Pancreatic Enzymes After Gastrectomy Trial

Gastrectomy

Germany
University of Florida

Completed

Fibrinolytic Therapy Versus Medical Thoracoscopy

Pleural Diseases

United States
Genzyme, a Sanofi Company

Completed

Growth and Development Study of Alglucosidase Alfa

Glycogen Storage Disease Type II (GSD-II) | Acid Maltase Deficiency Disease | Pompe Disease

United States
Megalabs
Azidus Laboratories

Not yet recruiting

Comparative Study of Two Recombinant Human Erythropoietin Products on Chronic Kidney Disease Patients (ENCASE)

Anemia of Chronic Kidney Disease

Uruguay
Hoffmann-La Roche

Completed

A Study to Assess All-Cause Mortality and Cardiovascular Morbidity in Participants With Chronic Kidney Disease (CKD) on Dialysis and Those Not on Renal Replacement Therapy Receiving Methoxy Polyethylene Glycol-Epoetin Beta (Mircera) or Reference Erythropoietin Stimulating Agents (ESAs)

Chronic Renal Anemia

Belgium, Brazil, United Kingdom, Serbia, Spain, Germany, Korea, Republic of, Turkey, Lithuania, Italy, Czechia, Argentina, Australia, Croatia, France, Greece, Israel, Malaysia, Mexico, Panama, Philippines, Poland, Russian Federation, ... and more
Genzyme, a Sanofi Company

Completed

Exploratory Muscle Biopsy Assessment Study in Patients With Late-Onset Pompe Disease Treated With Alglucosidase Alfa

Glycogenesis 2 Acid Maltase Deficiency | Pompe Disease (Late-Onset) | Glycogen Storage Disease Type II (GSD II)

United States, Netherlands, United Kingdom, Germany
Alexion Pharmaceuticals, Inc.
Xcenda, LLC

Active, not recruiting

Patient Reported Outcomes in Adults With Pediatric-onset Hypophosphatasia Treated With Strensiq® (Asfotase Alfa)

Hypophosphatasia

United States
Genzyme, a Sanofi Company

Terminated

A Study to Evaluate the Efficacy and Safety of Alglucosidase Alfa Produced at the 4000 L Scale for Pompe Disease

Pompe Disease

United States
Sanofi
Pulse Infoframe Ltd.

Recruiting

A Real-world Long-term Safety and Immunogenicity Study of Olipudase Alfa Therapy in Pediatric Patients Less Than 2 Years of Age With Acid Sphingomyelinase Deficiency (ASMD)

Niemann-Pick Diseases | Acid Sphingomyelinase Deficiency

United States
Sandoz

Completed

HX575 Epoetin Alfa Subcutaneously (s.c.) in Chronic Kidney Disease (CKD) (SENSE)

Chronic Kidney Disease

Russian Federation, Germany, Italy, Poland, Romania, Turkey, Ukraine
Celgene
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway...

Active, not recruiting

A Study to Compare the Efficacy and Safety of Luspatercept (ACE-536) Versus Epoetin Alfa for the Treatment of Anemia Due to IPSS-R Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Participants Who Require Red Blood Cell Transfusions and Are ESA Naïve (COMMANDS)

Myelodysplastic Syndromes

United States, Australia, Austria, Belgium, Canada, Czechia, France, Germany, Greece, Hungary, Israel, Italy, Japan, Korea, Republic of, Lithuania, Netherlands, Poland, Portugal, Russian Federation, Spain, Sweden, Switzerland, Taiwan, Turke... and more
Sandoz

Completed

Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa (ACCESS)

Anemia | Chronic Kidney Disease (CKD)

United States
Genzyme, a Sanofi Company

Active, not recruiting

Avalglucosidase Alfa French Post-trial Access for Participants With Pompe Disease (PTA Avalglucosidase)

Glycogen Storage Disease Type II

France
Genzyme, a Sanofi Company

Active, not recruiting

A Study to Assess Safety and Efficacy of Avalglucosidase Alfa Administered Every Other Week in Pediatric Patients With Infantile-onset Pompe Disease Previously Treated With Alglucosidase Alfa (Mini-COMET)

Glycogen Storage Disease Type II-Pompe's Disease

United States, France, Japan, Taiwan, United Kingdom
Amgen

Completed

Darbepoetin Alfa MDS Companion Protocol

Myelodysplastic Syndrome (MDS)

Belgium

Search clinical trials for: dornase alfa [Pulmozyme®]

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belarus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations